Dr. Robert Fremeau
Founder and CEO
Experienced R&D; leader with 20+ years of experience in academia and industry.
About BrainStorm Therapeutics
Integrating patient iPSC-derived brain organoid disease models with cutting-edge computational tools of deep learning and network medicine to transform CNS drug discovery.
Patient inspired, ML/AI-powered
Discovering and developing breakthrough medicines for complex neurological diseases.
Precision medicine approach
Genetically validated targets that drive human disease biology.
Experienced team
BrainStorm is led by an experienced team of neuroscientists, stem cell biologists, and drug developers.
Proprietary technology
We de-risk clinical translation using patient biology, biomarker-based screening, and advanced data analytics.
AI/ML powered
Leveraging deep learning and network medicine.
Our mission
To discover and develop breakthrough medicines for complex neurological disorders by integrating patient-derived iPSC models of brain disease, biomarker-based screening, and the computational tools of deep learning and network medicine to drive successful clinical outcomes faster at a reduced cost.
Our team
BrainStorm is led by an experienced team of drug hunters, neuroscientists, and stem cell biologists with a shared strategic vision to transform CNS drug discovery by leveraging a robust discovery engine combining human biology with the power of machine learning.
Dr. Maya Gosztyla
Co-founder and CSO
Neurobiologist with 5+ years of experience in cortical organoid disease models and applications of bioinformatics/machine learning in drug discovery.
Dr. Alysson Muotri
Stem cell and brain organoid pioneer
Created the first human organoid models for neurodevelopmental disorders.
Dr. James Treanor
Experienced biotech C-suite officer
Current BOD, SAB member, and former CEO at ADRx, Inc.
Dr. Mark H. Norman
Innovative medicinal chemist
30+ years of drug discovery and development experience.
Dr. Edoardo Marcora
Computational biology, software development, and genetics expertise
Professor of Genetics, Genomic Sciences, and Neuroscience, Mount Sinai Icahn School of Medicine; member of the Icahn Genomics Institute.
Dr. Blake Anson
Business development professional with deep commercial experience
19+ years building new markets and driving paradigm-shifting tools into biopharma, government, and academic organizations.
What drives us
Patient focused
Our approach is driven by the needs, experiences, and preferences of patients, ensuring that their voices and perspectives guide decision-making and improvements in the healthcare system.
Thought leadership
By driving meaningful discussions and inspiring others with valuable insights, we are establishing ourselves as leaders and innovative thinkers in the scientific world.
Accelerating progress
Our dynamic and proactive effort to expedite advancements and make significant strides in our field is driving positive change and innovation at a faster pace.
Our vision
- Be pioneers within the field
- Transform patient lives
- Uncover new therapies
- Collaborative network
- Long-term impact
Our values
- Innovation
- Patient-centricity
- Global impact
- Collaboration
- Excellence
Get in touch
Talk to us about our precision neuroscience platform, our Parkinson’s disease program, or working with the BrainStorm team.